Cancer Stem Cells

Impact, Heterogeneity, and Uncertainty

Jeffrey A. Magee, Elena Piskounova, Sean J. Morrison

Research output: Contribution to journalArticle

686 Citations (Scopus)

Abstract

The differentiation of tumorigenic cancer stem cells into nontumorigenic cancer cells confers heterogeneity to some cancers beyond that explained by clonal evolution or environmental differences. In such cancers, functional differences between tumorigenic and nontumorigenic cells influence response to therapy and prognosis. However, it remains uncertain whether the model applies to many, or few, cancers due to questions about the robustness of cancer stem cell markers and the extent to which existing assays underestimate the frequency of tumorigenic cells. In cancers with rapid genetic change, reversible changes in cell states, or biological variability among patients, the stem cell model may not be readily testable.

Original languageEnglish (US)
Pages (from-to)283-296
Number of pages14
JournalCancer Cell
Volume21
Issue number3
DOIs
StatePublished - Mar 20 2012

Fingerprint

Neoplastic Stem Cells
Uncertainty
Neoplasms
Clonal Evolution
Stem Cells

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

Cancer Stem Cells : Impact, Heterogeneity, and Uncertainty. / Magee, Jeffrey A.; Piskounova, Elena; Morrison, Sean J.

In: Cancer Cell, Vol. 21, No. 3, 20.03.2012, p. 283-296.

Research output: Contribution to journalArticle

Magee, Jeffrey A. ; Piskounova, Elena ; Morrison, Sean J. / Cancer Stem Cells : Impact, Heterogeneity, and Uncertainty. In: Cancer Cell. 2012 ; Vol. 21, No. 3. pp. 283-296.
@article{40d22a5a9ba749f4852e133b0f1e554f,
title = "Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty",
abstract = "The differentiation of tumorigenic cancer stem cells into nontumorigenic cancer cells confers heterogeneity to some cancers beyond that explained by clonal evolution or environmental differences. In such cancers, functional differences between tumorigenic and nontumorigenic cells influence response to therapy and prognosis. However, it remains uncertain whether the model applies to many, or few, cancers due to questions about the robustness of cancer stem cell markers and the extent to which existing assays underestimate the frequency of tumorigenic cells. In cancers with rapid genetic change, reversible changes in cell states, or biological variability among patients, the stem cell model may not be readily testable.",
author = "Magee, {Jeffrey A.} and Elena Piskounova and Morrison, {Sean J.}",
year = "2012",
month = "3",
day = "20",
doi = "10.1016/j.ccr.2012.03.003",
language = "English (US)",
volume = "21",
pages = "283--296",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - Cancer Stem Cells

T2 - Impact, Heterogeneity, and Uncertainty

AU - Magee, Jeffrey A.

AU - Piskounova, Elena

AU - Morrison, Sean J.

PY - 2012/3/20

Y1 - 2012/3/20

N2 - The differentiation of tumorigenic cancer stem cells into nontumorigenic cancer cells confers heterogeneity to some cancers beyond that explained by clonal evolution or environmental differences. In such cancers, functional differences between tumorigenic and nontumorigenic cells influence response to therapy and prognosis. However, it remains uncertain whether the model applies to many, or few, cancers due to questions about the robustness of cancer stem cell markers and the extent to which existing assays underestimate the frequency of tumorigenic cells. In cancers with rapid genetic change, reversible changes in cell states, or biological variability among patients, the stem cell model may not be readily testable.

AB - The differentiation of tumorigenic cancer stem cells into nontumorigenic cancer cells confers heterogeneity to some cancers beyond that explained by clonal evolution or environmental differences. In such cancers, functional differences between tumorigenic and nontumorigenic cells influence response to therapy and prognosis. However, it remains uncertain whether the model applies to many, or few, cancers due to questions about the robustness of cancer stem cell markers and the extent to which existing assays underestimate the frequency of tumorigenic cells. In cancers with rapid genetic change, reversible changes in cell states, or biological variability among patients, the stem cell model may not be readily testable.

UR - http://www.scopus.com/inward/record.url?scp=84858608410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858608410&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2012.03.003

DO - 10.1016/j.ccr.2012.03.003

M3 - Article

VL - 21

SP - 283

EP - 296

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 3

ER -